Keeping the blood flowing: venous thromboembolism prophylaxis and treatment
SA Pharmaceutical Journal · 01.10.2026 · 93 (5) · 37-44
DOI: 10.36303/sapj.5074 ↗Kurz gefasst
Fachartikel in der Zeitschrift SA Pharmaceutical Journal, erschienen am 01.10.2026. Verfasst von H Badenhorst und 2 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, continues to be a significant cause of preventable morbidity and mortality globally, with notable under-treatment in South Africa. This review explores the pathophysiology, prevention, and treatment of venous thromboembolism, focusing on current practices in South Africa. Current pharmacotherapeutic options, such as unfractionated heparin, low-molecular-weight heparins, warfarin, direct oral anticoagulants, fondaparinux, and fibrinolytic agents, are discussed from a pharmacokinetic and pharmacodynamic view, with emphasis on their clinical use as per the South African Essential Medicines List and Standard Treatment Guidelines.
Zitieren
APA
Badenhorst, H., Amm, J., & Cordier, W. (2026). Keeping the blood flowing: venous thromboembolism prophylaxis and treatment. SA Pharmaceutical Journal, 93(5), 37-44. https://doi.org/10.36303/sapj.5074
Vancouver
Badenhorst H, Amm J, Cordier W. Keeping the blood flowing: venous thromboembolism prophylaxis and treatment. SA Pharmaceutical Journal. 2026;93(5):37-44. doi:10.36303/sapj.5074
BibTeX
@article{Badenhorst2026,
author = {Badenhorst, H and Amm, J and Cordier, W},
title = {Keeping the blood flowing: venous thromboembolism prophylaxis and treatment},
journal = {SA Pharmaceutical Journal},
year = {2026},
volume = {93},
number = {5},
pages = {37--44},
doi = {10.36303/sapj.5074}
}
EUVIMED